Cloning and analysis of PEDF receptor as an anti-angiogenic factor.
Cloning and analysis of PEDF receptor as an anti-angiogenic factor.
批准号:
16390537
负责人:
NAKAHAMA Ken-ichi
金额:
$9.28万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005
中文摘要
本课题的目的是鉴定PEDF的受体,并分析其功能。1、PEDF抗血管生成活性部位的鉴定。(1)细胞外基质结合域突变体我们寻找了PEDF发挥抗血管生成活性的关键区域。定点诱变用于制备PEDF突变体。这些突变体表达肝素结合缺陷型PEDF(R148 A)、葡萄糖基化缺陷型(N284 Q)和胶原结合缺陷型(D299 N)。将稳定表达这些突变体的HeLa细胞移植到裸鼠体内。3周后,定量肿瘤大小和肿瘤中的血管密度。PEDF野生型表达肿瘤小于模拟表达肿瘤。另一方面,表达D299 N突变体的肿瘤与表达模拟物的肿瘤大小相同。肿瘤内微血管密度与肿瘤大小相关。这些结果表明PEDF的胶原结合结构域是发挥抗血管生成作用所必需的。(2)C端缺失突变体为了寻找PEDF的最小必需序列,用一系列缺失突变体表达载体转染HEK 293细胞。不幸的是,这些截短的突变蛋白保留在细胞中。因此,我们决定使用全长PEDF作为PEDF受体的配体。我们成功地用镍柱纯化了His 6-PEDF-DsRed融合蛋白。接下来,我们将开始PEDF受体的表达克隆。2、PEDF的转录调控我们也发现了PEDF的转录调控。我们分离了PEDF的12 kb启动子区。我们研究了EPC-1/PEDF启动子活性是否受到细胞老化的影响,使用人二倍体肺成纤维细胞培养。我们发现EPC-1/PEDF基因的启动子/增强子区位于转录起始位点上游1760 bp处,受衰老和细胞周期的调控。
英文摘要
The aim of this project was to identify the receptor of PEDF, and analyze the function of this receptor.1, Identification of active site of PEDF in anti-angiogenic effect.(1) Extracellular matrix binding domain mutantsWe searched an essential region to exert anti-angiogenic activity of PEDF. Site direct mutagenesis was used to make PEDF mutants. These mutants express heparin binding deficient PEDF (R148A), glucosylation deficient (N284Q) and collagen binding deficient (D299N). HeLa cells expressing these mutants stably were grafted to nude mouse. After 3 weeks, tumor size and blood vessel density in the tumor were quantified. The PEDF wild type expressing tumor was smaller than mock expressing tumor. On the other hand, D299N mutant expressing tumor was the same size as the mock expressing tumor. The density of microvessel in tumor was correlated with the size of tumor. These results suggest the collagen binding domain of PEDF is essential to exert anti-angiogenic effect.(2) C-terminus deletion mutantsTo find the minimal essential sequence of PEDF, HEK293 cells were transfected with a series of deletion mutant expression vectors. Unfortunately, these truncated mutant proteins retained in the cell. Therefore, we decided to use the full-length PEDF as a ligand for PEDF receptor. Now we succeeded in the purification of His6-PEDF-DsRed fusion protein using nickel column. Next, we will begin the expression cloning of PEDF receptor.2, Transcriptional regulation of PEDFWe also find the transcriptional regulation of PEDF. We isolated the 12kb promoter region of PEDF. We examined whether or not EPC-1/PEDF promoter activity was affected by the cellular ageing using human diploid lung fibroblast cells in culture. We find the promoter/enhancer region of EPC-1/PEDF existed at more than 1760bp upstream from the transcriptional initiation site of the gene, and was regulated by both aging and cell cycle.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
--
发表时间:
2005-01
期刊:
Molecular vision
影响因子:
2.2
作者:
[K. Ohno-Matsui;S. Ichinose;K. Nakahama;Takeshi Yoshida;A. Kojima;M. Mochizuki;I. Morita]
通讯作者:
K. Ohno-Matsui;S. Ichinose;K. Nakahama;Takeshi Yoshida;A. Kojima;M. Mochizuki;I. Morita
DOI:
10.1007/s11010-006-2680-0
发表时间:
2006-12-01
期刊:
MOLECULAR AND CELLULAR BIOCHEMISTRY
影响因子:
4.3
作者:
[Kojima, Toshihiko, Nakahama, Ken-ichi, Morita, Ikuo]
通讯作者:
Morita, Ikuo
DOI:
10.1016/j.bbrc.2005.07.140
发表时间:
2005-09-30
期刊:
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子:
3.1
作者:
[Hosomichi, J, Yasui, N, Morita, I]
通讯作者:
Morita, I
Mechanism underlying anti-cancer effect by cell-cell communication via gap junction
-
批准号:15K15691
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.25万
-
财政年份:2015
-
负责人:NAKAHAMA Ken-ichi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
-
批准号:82372743
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈卓佳
-
依托单位:
脊髓电刺激活化Na(V)1.1阳性GABA神经元持续缓解癌痛
-
批准号:82371223
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:闻大翔
-
依托单位:
丁酸梭菌代谢物(如丁酸、苯乳酸)通过MYC-TYMS信号轴影响结直肠癌化疗敏感性的效应及其机制研究
-
批准号:82373139
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:李孟鸿
-
依托单位:
均相液相生物芯片检测系统的构建及其在癌症早期诊断上的应用
-
批准号:82372089
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:李万万
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
-
批准号:82371997
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张春富
-
依托单位:
BRPF1 m6A修饰异常通过重塑BCAT1超级增强子介导Setd2缺陷型肾癌支链氨基酸代谢成瘾的机制研究
-
批准号:82372724
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:何竑超
-
依托单位:
基于影像代谢重塑可视化的延胡索酸水合酶缺陷型肾癌危险性分层模型的研究
-
批准号:82371912
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:吴广宇
-
依托单位:
EGFR通过激活β-catenin重塑肿瘤微环境代谢调控肿瘤免疫逃逸的分子机制研究
-
批准号:32100574
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:邵飞
-
依托单位:
脯氨酸羟化酶EglN1转位到线粒体介导乳腺癌细胞适应缺氧应激的机制研究
-
批准号:32100570
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:闫朝君
-
依托单位: